31719-76-3Relevant articles and documents
Design, synthesis and biological activity of novel substituted 3-benzoic acid derivatives as MtDHFR inhibitors
Dias, Marcio Vinícius Bertacine,Ferreira, Glaucio Monteiro,Kronenberger, Thales,Parise-Filho, Roberto,Pavan, Fernando Rogério,Poso, Antti,Ribeiro, Jo?o Augusto,Tavares, Maurício Temotheo,Trossini, Gustavo Henrique Goulart,da Silva Santos, Soraya,de Souza, Alfredo Danilo Ferreira
, (2020/07/03)
The enzyme dihydrofolate reductase from M. tuberculosis (MtDHFR) has a high unexploited potential to be a target for new drugs against tuberculosis (TB), due to its importance for pathogen survival. Preliminary studies have obtained fragment-like molecule
Metal-Free I2-Catalyzed Highly Selective Dehydrogenative Coupling of Alcohols and Cyclohexenones
Liang, Yu-Feng,Yuan, Yizhi,Shen, Tao,Song, Song,Jiao, Ning
, p. 233 - 240 (2018/02/19)
The I2 catalyzed highly selective oxidative condensation of cyclohexenones and alcohols for the synthesis of aryl alkyl ethers has been described. DMSO is employed as the mild terminal oxidant. This novel methodology offers a metal-free reaction condition, operational simplicity and broad substrate scope to afford valuable products from inexpensive reagents. Various meta-substituted aromatic ethers which are hardly synthesized from the reported methods requiring meta-substituted phenols, are efficiently prepared by the present protocol.
Benzamide compound and application thereof in preparation of medicines for inhibiting cancer cell proliferation and/or treating cancer
-
Paragraph 0034, (2017/08/25)
The invention discloses a benzamide compound and an application thereof in preparation of medicines for inhibiting cancer cell proliferation and/or treating cancer. The compound has an ability to inhibit the cancer cell proliferation, and the purpose of cancer treatment is achieved. In particular, the compound has excellent cancer cell proliferation inhibiting activity on inhibiting human lung cancer cells A549, human gastric cancer cells MGC80-3, human hepatoma cells HepG2 and human colon cancer cells HCT116. The compound has the following structure described in the specification, wherein R1 is hydrogen, fluorine, chlorine, bromine, iodine, alkyl, alkoxy, alkyl carbonyl, alkoxy carbonyl, alkyl amide, nitro, cyano, aryl or heteroaryl, and R2 is hydrogen, fluorine, chlorine, bromine, iodine, alkyl, alkoxy, alkyl carbonyl, alkoxy carbonyl, alkyl amide, nitro, cyano, aryl or heteroaryl.
